Citigroup’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$12.7M Buy
28,400
+4,000
+16% +$1.87M 0.01% 1326
2025
Q4
$11.1M Sell
24,400
-3,900
-14% -$1.68M ﹤0.01% 1459
2025
Q3
$11.1M Hold
28,300
﹤0.01% 1407
2025
Q2
$12.6M Buy
28,300
+19,900
+237% +$9.17M 0.01% 1235
2025
Q1
$4.07M Sell
8,400
-55,100
-87% -$25.7M ﹤0.01% 2091
2024
Q4
$25.6M Buy
63,500
+16,300
+35% +$7.56M 0.02% 823
2024
Q3
$22M Buy
47,200
+17,100
+57% +$8.21M 0.01% 892
2024
Q2
$14.1M Sell
30,100
-32,600
-52% -$14.1M 0.01% 1070
2024
Q1
$26.2M Sell
62,700
-27,800
-31% -$11.8M 0.02% 766
2023
Q4
$36.8M Buy
90,500
+35,300
+64% +$13M 0.03% 577
2023
Q3
$19.2M Buy
55,200
+34,700
+169% +$12.1M 0.01% 791
2023
Q2
$7.21M Buy
+20,500
New +$6.91M ﹤0.01% 1290
2023
Q1
Sell
-12,000
Closed -$3.47M 5895
2022
Q4
$3.47M Sell
12,000
-15,000
-56% -$4.57M ﹤0.01% 1684
2022
Q3
$7.82M Buy
27,000
+10,200
+61% +$2.93M 0.01% 1274
2022
Q2
$4.73M Sell
16,800
-118,400
-88% -$31.7M ﹤0.01% 1572
2022
Q1
$35.3M Buy
135,200
+128,200
+1,831% +$30.4M 0.02% 640
2021
Q4
$1.54M Hold
7,000
﹤0.01% 2841
2021
Q3
$1.27M Sell
7,000
-8,600
-55% -$1.68M ﹤0.01% 2902
2021
Q2
$3.15M Buy
+15,600
New +$3.26M ﹤0.01% 2300
2021
Q1
Sell
-59,100
Closed -$14M 7470
2020
Q4
$14M Sell
59,100
-1,300
-2% -$298K 0.01% 1292
2020
Q3
$16.4M Sell
60,400
-21,100
-26% -$5.82M 0.01% 1017
2020
Q2
$23.7M Sell
81,500
-4,600
-5% -$1.25M 0.02% 736
2020
Q1
$20.5M Sell
86,100
-150,600
-64% -$34.5M 0.02% 721
2019
Q4
$51.8M Buy
236,700
+34,400
+17% +$6.96M 0.04% 495
2019
Q3
$34.3M Buy
202,300
+26,900
+15% +$4.76M 0.03% 629
2019
Q2
$32.2M Sell
175,400
-5,700
-3% -$996K 0.03% 652
2019
Q1
$33.3M Buy
181,100
+95,400
+111% +$17.6M 0.03% 560
2018
Q4
$14.2M Buy
85,700
+28,600
+50% +$4.96M 0.01% 1024
2018
Q3
$11M Sell
57,100
-10,600
-16% -$1.89M 0.01% 1222
2018
Q2
$11.5M Buy
67,700
+31,600
+88% +$4.9M 0.01% 1189
2018
Q1
$5.88M Sell
36,100
-5,400
-13% -$882K ﹤0.01% 1632
2017
Q4
$6.22M Sell
41,500
-31,300
-43% -$4.63M 0.01% 1635
2017
Q3
$11.1M Buy
72,800
+32,000
+78% +$4.82M 0.01% 1166
2017
Q2
$5.26M Sell
40,800
-46,200
-53% -$5.56M ﹤0.01% 1655
2017
Q1
$9.51M Buy
87,000
+34,300
+65% +$3.02M 0.01% 1169
2016
Q4
$3.88M Sell
52,700
-900
-2% -$73.2K ﹤0.01% 2124
2016
Q3
$4.67M Buy
53,600
+11,800
+28% +$1.12M ﹤0.01% 1729
2016
Q2
$3.6M Buy
41,800
+3,200
+8% +$277K ﹤0.01% 1872
2016
Q1
$3.07M Buy
38,600
+4,000
+12% +$362K ﹤0.01% 2031
2015
Q4
$4.35M Sell
34,600
-9,800
-22% -$1.18M ﹤0.01% 1816
2015
Q3
$4.62M Buy
44,400
+21,000
+90% +$2.7M ﹤0.01% 1730
2015
Q2
$2.89M Buy
23,400
+10,200
+77% +$1.29M ﹤0.01% 2214
2015
Q1
$1.56M Sell
13,200
-119,000
-90% -$14.3M ﹤0.01% 2692
2014
Q4
$15.7M Buy
132,200
+47,900
+57% +$5.39M 0.01% 942
2014
Q3
$9.47M Sell
84,300
-179,200
-68% -$17.1M 0.01% 1327
2014
Q2
$24.9M Buy
263,500
+120,500
+84% +$8.45M 0.02% 658
2014
Q1
$10.1M Sell
143,000
-24,700
-15% -$1.96M 0.01% 1154
2013
Q4
$12.5M Buy
167,700
+92,000
+122% +$6.41M 0.01% 1082
2013
Q3
$5.74M Sell
75,700
-113,500
-60% -$9.03M 0.01% 1641
2013
Q2
$15.1M Buy
+189,200
New +$13.9M 0.01% 815

Other funds holding VRTX

Citigroup's VRTX Position: Q1 2026 in Review

Citigroup increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q1 2026, buying an estimated $66.6M and bringing the position to 682,807 shares worth $305M. The position accounts for 0.13% of the portfolio, ranked #153.

Citigroup first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Citigroup held 682,807 shares of Vertex Pharmaceuticals worth $305M as of Q1 2026.
  • Citigroup bought 142,877 Vertex Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
  • Vertex Pharmaceuticals made up 0.13% of Citigroup's portfolio in Q1 2026, its #153 holding.
  • Citigroup first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.